Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 1, 2025
Hydreight Achieves Record Revenue and Profitability Milestone in Q4 2024 Audited Results
GlobeNewswire
·
May 1, 2025
Record 2024 Topline¹ revenue of $22.32 million, up 31% from 2023 Record 2024 GAAP revenue of $16.04 million, up 39% from 2023 2024 Adjusted EBITDA¹ of +490K compared to ($1.38) million in 2023 2024 gross margin of $5.75 million, up from 8% from 2023 Q4 …
Used and new teen vehicles for every budget
GlobeNewswire
·
May 1, 2025
ARLINGTON, Va., and YONKERS, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- Families with newly licensed teens have a wide range of options this year when it comes to safe vehicles for their novice driver. An updated list of suggested vehicles for teens from the …
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC
GlobeNewswire
·
May 1, 2025
TAIPEI, Taiwan, May 01, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (“OBI”), a clinical stage oncology company（4174.TWO), today announced that the U.S. Food and Drug Administration (FDA） has cleared an investigational new drug （IND） application for OBI-902, …
浩鼎ADC OBI-902临床试验获美国FDA核准 将启动Trop-2靶向ADC 1/2期临床研究
GlobeNewswire
·
May 1, 2025
台湾, May 01, 2025 (GLOBE NEWSWIRE) -- 致力于癌症创新疗法研发的台湾浩鼎生技（4174.TWO）今（5/1）日（美国时间4/30）宣布，旗下新药OBI-902已获美国食品药物管理局（FDA）核准临床试验申请（IND），将展开一期/二期临床试验。这项试验预计招募晚期实体肿瘤患者。浩鼎视此次通过IND，为开发进程的重要里程碑，代表此一新世代Trop-2 ADC，将为未被满足医疗需求的患者提供新的治疗希望。 浩鼎执行长王慧君博士表示，即将开展的OBI-902-001 …
浩鼎ADC OBI-902臨床試驗獲美國FDA核准 將啟動Trop-2靶向ADC 1/2期臨床研究
GlobeNewswire
·
May 1, 2025
台灣, May 01, 2025 (GLOBE NEWSWIRE) -- 致力於癌症創新療法研發的台灣浩鼎生技 （4174.TWO） 今（5/1）日（美國時間4/30） 宣布，旗下新藥OBI-902已獲美國食品藥物管理局（FDA）核准臨床試驗申請（IND），將展開一期/二期臨床試驗。這項試驗預計招募晚期實體腫瘤患者。浩鼎視此次通過IND，為開發進程的重要里程碑，代表此一新世代Trop-2 ADC，將為未被滿足醫療需求的患者提供新的治療希望。 浩鼎執行長王慧君博士表示，即將開展的OBI-902-001 …